These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 18953274)

  • 41. [Nesiritide in heart failure: commercial success or therapeutic advance?].
    Stampfli T; Perrier A
    Rev Med Suisse; 2006 Jan; 2(50):295-8. PubMed ID: 16503047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nesiritide utilization evaluation in a university teaching hospital.
    Cheng JW; Merl MY; Nguyen HM; Caliendo GC; Meyers J
    J Clin Pharm Ther; 2005 Oct; 30(5):447-53. PubMed ID: 16164491
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failure.
    Saltzberg MT
    Rev Cardiovasc Med; 2004; 5 Suppl 4():S17-27. PubMed ID: 15627915
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing outcomes in the patient with acute decompensated heart failure.
    Mehra MR
    Am Heart J; 2006 Mar; 151(3):571-9. PubMed ID: 16504617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nesiritide: the clinical experience.
    Weeks SG
    Can J Cardiol; 2008 Jul; 24 Suppl B(Suppl B):19B-21B. PubMed ID: 18629384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Brain natriuretic peptide (nesiritide) in the treatment of heart failure.
    Bettencourt P
    Cardiovasc Drug Rev; 2002; 20(1):27-36. PubMed ID: 12070532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BNP in decompensated heart failure: diagnostic, prognostic and therapeutic potential.
    Burger MR; Burger AJ
    Curr Opin Investig Drugs; 2001 Jul; 2(7):929-35. PubMed ID: 11757793
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database.
    Costanzo MR; Johannes RS; Pine M; Gupta V; Saltzberg M; Hay J; Yancy CW; Fonarow GC
    Am Heart J; 2007 Aug; 154(2):267-77. PubMed ID: 17643575
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial.
    Tang WHW; Dupont M; Hernandez AF; Voors AA; Hsu AP; Felker GM; Butler J; Metra M; Anker SD; Troughton RW; Gottlieb SS; McMurray JJ; Armstrong PW; Massie BM; Califf RM; O'Connor CM; Starling RC
    JACC Heart Fail; 2015 Jan; 3(1):40-49. PubMed ID: 25453534
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy in the emergency department.
    Emerman CL
    Rev Cardiovasc Med; 2003; 4 Suppl 7():S13-20. PubMed ID: 14668696
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure.
    Chow SL; O'Barr SA; Peng J; Chew E; Pak F; Quist R; Patel P; Patterson JH; Heywood JT
    J Card Fail; 2011 Mar; 17(3):181-7. PubMed ID: 21362524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute decompensated heart failure: challenges and opportunities.
    Fonarow GC
    Rev Cardiovasc Med; 2007; 8 Suppl 5():S3-12. PubMed ID: 18192951
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nesiritide: a new therapy for the treatment of heart failure.
    Maisel AS
    Cardiovasc Toxicol; 2003; 3(1):37-42. PubMed ID: 12668889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
    Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
    Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of nesiritide for acute decompensated heart failure: recent literature and upcoming trials.
    Hiestand B; Abraham WT
    Curr Cardiol Rep; 2007 May; 9(3):182-6. PubMed ID: 17470330
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
    Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
    Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nesiritide for acute decompensated heart failure: does the benefit justify the risk?
    Sackner-Bernstein J; Aaronson KD
    Curr Cardiol Rep; 2007 May; 9(3):187-93. PubMed ID: 17470331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes of patients hospitalized for acute decompensated heart failure: does nesiritide make a difference?
    Carroll RJ; Mulla ZD; Hauck LD; Westbrook A
    BMC Cardiovasc Disord; 2007 Nov; 7():37. PubMed ID: 18039381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. B-type natriuretic peptide: spectrum of application. Nesiritide (recombinant BNP) for heart failure.
    Fonarow GC
    Heart Fail Rev; 2003 Oct; 8(4):321-5. PubMed ID: 14574051
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of nesiritide in the management of acute decompensated heart failure.
    Kayser SR
    Prog Cardiovasc Nurs; 2002; 17(2):89-95. PubMed ID: 11986542
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.